TD Cowen analyst Marc Frahm reiterated a Buy rating on Elevation Oncology (NASDAQ: ELEV).The analyst commented, "EO-3021's (CLDN18.2 ADC) ongoing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE